Search

Your search keyword '"Montastruc, Jean‐Louis"' showing total 302 results
Start Over Author "Montastruc, Jean‐Louis" Search Limiters Full Text
302 results on '"Montastruc, Jean‐Louis"'

17. Pharmacovigilance : actualités et perspectives

Author

Montastruc, Jean-Louis, Tillement, Jean-Paul, Bontoux, Daniel, Bounhoure, Jean-Paul, Bouvenot, Gilles, Buffet, Catherine, Delaveau, Pierre, Eléfant, Elisabeth, Giroud, Jean-Paul, Gonthier, Régis, Goullé, Jean-Pierre, Jaillon, Patrice, Joly, Pierre, Juillet, Yves, Lhermitte, Michel, Menkès, Charles-Joël, Queneau, Patrice, Safavian, Alain A., Trêves, Richard, and Doucet, Jean

Published
2012
Full Text
View/download PDF

18. A major rethink is needed

Author

Herxheimer, Andrew, Vohra, Sunita, Montastruc, Jean-Louis, and Edwards, Ralph

Published
2012

19. Place des génériques dans la prescription

Author

Bontoux, Daniel, Bounhoure, Jean-Paul, Bouvenot, Gilles, Buffet, Catherine, Couvreur, Patrick, Delatour, Paul, Delaveau, Pierre, Eléfant, Elisabeth, Gonthier, Régis, Goullé, Jean-Pierre, Imbs, Jean-Louis, Jaillon, Patrice, Joly, Pierre, Juillet, Yves, Lhermitte, Michel, Menkès, Charles-Joël, Montastruc, Jean-louis, Netter, Patrick, Queneau, Patrice, Safavian, Alain-Abbas, Sassard, Jean, Tillement, Jean-Paul, Trèves, Richard, Vigneron, Claude, and Doucet, Jean

Published
2012
Full Text
View/download PDF

20. Adverse drug events

Author

Sommet, Agnès, Castot, Anne, and Montastruc, Jean-Louis

Published
2009

21. Bleeding in patients on concurrent treatment with serotonin reuptake inhibitor (SRI) and acetylsalicylic acid (ASA) compared with ASA alone: a pharmacovigilance study.

Author

Montastruc, Jean‐Louis and Bura‐Rivière, Alessandra

Subjects
*SEROTONIN uptake inhibitors, *ASPIRIN, *BLOOD platelet aggregation, *DRUG side effects, *PLATELET aggregation inhibitors, *HEMORRHAGE
Abstract

A pharmacovigilance study compared the risk of bleeding in patients taking a combination of serotonin reuptake inhibitor (SRI) antidepressants and acetylsalicylic acid (ASA) versus ASA alone. The study found a higher risk of bleeding reports with SRI and platelet aggregation inhibitors (PAI) compared to PAI alone, but no significant risk with SRI and ASA alone. The results suggest that ASA may be safer than other PAI in terms of bleeding risk for patients treated with SRI. Further studies are needed to confirm these findings. [Extracted from the article]

Published
2024
Full Text
View/download PDF

23. Bilan du suivi de PharmacoVigilance des vaccins contre la grippe A(H1N1)v durant la campagne 2009-2010 en France

Author

Autret-Leca, E, Baldin B, B, Bavoux, F, Bénard-Laribière, A, Biour, M, Beyens, MN, Colin, F, Cocquerel, A, Crepin, S, Décréau-Gaillon, G, Dos Santos, S, Eftekhari, P, Favrelière, S, Gautier, S, Gras-Champel, V, Javot, L, Jean-Pastor, MJ, Le Beller, C, Lebrun-Vignes, B, Millaret, A, Perrazi, A, Pinzani, V, Riché, C, Schir, E, Sgro, C, Tebacher-Alt, M, Trenque, T, Valnet-Rabier, MB, Veyrac, G, and Montastruc, Jean-Louis

Published
2011
Full Text
View/download PDF

26. Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010–2019.

Author

Montastruc, Jean‐Louis

Subjects
*DRUG side effects, *PEDIATRIC pharmacology, *CLINICAL pharmacology, *CENTRAL nervous system
Abstract

Aims: Adverse drug reactions (ADRs) represent a significant public health burden. There are few data on fatal ADRs in children. This population is particularly at risk due to metabolic and physiological immaturity, frequent off‐label drug use and limited paediatric clinical pharmacology studies. The study investigated the main characteristics of drug‐related deaths registered in World Health Organization pharmacovigilance database, during the past decade. Methods: Fatal outcomes registered between 2010 and 2019 in children (<18 y) and reported by physicians were investigated. Age, sex and suspected drugs were described and disproportionality analyses investigated differences according to sex, age and continents with calculation of reporting odds ratio and its 95% confidence interval. Results: Among the 1 198 560 reports registered in children, 1585 (0.13%) were fatal. They occurred mainly in boys, aged 28 days–23 months. Reports mostly came from the Americas and Europe and involved, besides anti‐infectious drugs (mainly vaccines), central nervous system (vigabatrin, paracetamol, methylphenidate...) and antineoplastic/immunomodulating (mainly thalidomide) and cardiovascular (mainly bosentan) drugs without major differences between boys and girls. Large differences were found according to continents and age. The risk of reporting was higher in boys, in children aged <23 months, in the Americas and Africa. Conclusion: Fatal ADRs represented a small part (around 1/1000) of total registered ADRs, occurred more frequently in boys and during the first 2 years of life. Beside anti‐infectious drugs (vaccines), neuropsychiatric drugs were the most frequently involved, with large differences according to continents and classes of age. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results